Differential diagnosis of depression and Alzheimer’s disease with the Addenbrooke's Cognitive Examination-Revised (ACE-R) by Augustinas Rotomskis et al.
Rotomskis et al. BMC Neurology  (2015) 15:57 
DOI 10.1186/s12883-015-0315-3RESEARCH ARTICLE Open AccessDifferential diagnosis of depression and
Alzheimer’s disease with the Addenbrooke's
Cognitive Examination-Revised (ACE-R)
Augustinas Rotomskis1*, Ramunė Margevičiūtė2, Arūnas Germanavičius3, Gintaras Kaubrys4, Valmantas Budrys4
and Albinas Bagdonas5Abstract
Background: One of the usual problems psychologists and clinicians face in clinical practice is differential
diagnostics of Alzheimer’s disease and depression. It has been reported that the ACE and ACE-R could discriminate
the cognitive dysfunctions due to depression from that due to dementia, although this is not uniform in all studies.
The current study aimed to evaluate the utility of the ACE-R to differentiate late-life onset depression (with severe
episode) from mild-moderate Alzheimer’s Disease (AD).
Methods: This study received approval from the Lithuanian Bioethics Committee. All participants were older than
50 years (mean age = 66.52 (±8.76) years). The study sample consisted of 295 individuals: 117 with severe depression, 85
with mild-moderate Alzheimer’s disease (AD), and 94 age, gender and education matched participants of control group.
Results: The ACE-R had high sensitivity (100%) and specificity (81%) at detecting cognitive impairments related to AD.
Patients with late-life onset depression (ACE-R mean 76.82, SD = 7.36) performed worse than controls (ACE-R mean 85.08,
SD = 7.2), but better than the AD group (ACE-R mean 54.74, SD = 12.19). Participants with late-life onset depression were
differentiated by mild impairment in the ACE-R total score with mild memory (13.79, SD = 6.29) and greater deficits in
letter fluency (3.65, SD = 1.21) than in semantic fluency (4.68, SD = 1.23). Participants with AD were differentiated by
severely impaired performance on attention and orientation (11.80, SD = 2.93), memory (8.25, SD = 3.47) and language
subtests (17.21, SD = 4.04), and moderately impaired performance on verbal fluency (6.07, SD = 2.74).
Conclusions: ACE-R has diagnostic accuracy in detecting people with AD and can be used in differential
diagnostics of late-life onset depression (severe episode) and AD. Diagnostic accuracy may be improved by
analyzing the neuropsychological profiles and using lower cutoffs for different age groups.
Keywords: Alzheimer’s disease, Late-life onset depression with severe episode, Addenbrooke’s cognitive
examination- revised, Differential diagnosticsBackground
The development of novel treatments for AD, aimed at
ameliorating symptoms and modifying disease processes
are likely to be the the most successful early in the disease,
which increases the need for early diagnosis [1]. The early
differential diagnosis between Alzheimer’s disease (AD) and
late-life-onset depression remains a diagnostic challenge in
neurology and psychiatry [2]. Patients presenting with com-
binations of cognitive, affective, and behavioral problems* Correspondence: rotomskis.augustinas@gmail.com
1Vilnius University Faculty of Philosophy, Universiteto st. 9/1, Vilnius, Lithuania
Full list of author information is available at the end of the article
© 2015 Rotomskis et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.pose a clinical conundrum. In some cases, it is difficult to
establish whether the cognitive impairment is secondary to
an affective disorder, or to organic dementing process. A
small proportion of depressed individuals present with sig-
nificant cognitive dysfunction, formerly known as depres-
sive pseudodementia, also termed “functional dementia”,
“memory disorder in the context of depressive illness”, or
“the dementia syndrome of depression” [3]. Accurate diag-
nosis is difficult in older adults for several reasons: patient
and family members may give confusing and conflicting in-
formation; depression and dementia may be attributed to
the normal effects of aging; dementia and depression oftentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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differential diagnosis of severe depression from early de-
mentia remains difficult, which leads to misdiagnosis of se-
vere depression as early dementia.
The differential diagnosis of early stage AD and late life
onset severe depression is especially difficult, because
these diseases greatly overlap in cognitive impairments.
Mild AD is characterized in the early stages by deficits in
episodic memory [5], which are particularly clear on tasks
requiring learning and retention of either verbal or non-
verbal information [6,7]. However, patients with severe de-
pression also tend to perform poorly on both verbal and
nonverbal memory tests [8-10]. To complicate matters
even further, difficult verbal episodic memory tasks such
as recall tasks often fail to discriminate accurately severe
depression patients from mild AD patients [11].
One important aspect of the clinical assessment of
cognitive impairment in depression should be identifying
cognitive screening instruments that differentiate the
cognitive deficits most characteristic of depression from
those that are most likely to reflect AD [12]. Unfortu-
nately, there are few empirical data on screening mea-
sures that effectively discriminate between the cognitive
presentations of AD and depression. In a study that il-
lustrates the diagnostic problem, the Short Cognitive
Evaluation Battery was found to demonstrate 94% sensi-
tivity and 85% specificity for discriminating AD from
non-demented and non-depressed controls, but there
was only 63% sensitivity with 96% specificity discriminat-
ing AD from individuals with depression symptoms [13].
Similar issues of test insensitivity in discriminating de-
pression are present in the Mini-Mental State Examin-
ation [14], which is widely used to estimate the severity
of cognitive impairment, but which is less sensitive to
milder cognitive impairment that might be expected in
depression because of a low ceiling of difficulty, narrow
range of cognitive abilities assessed, and differential sen-
sitivity to age, education and ethnicity [15]. Based on
current evidence, there are no screening measures that
are sufficiently valid for distinguishing among depression
and AD in a clinical setting, and this is even more of an
issue when depression and cognitive impairment occur
together. There is a need for multidimensional and easily
accessible dementia screening tools that would accur-
ately identify people suffering from AD and differentiate
them from those suffering from depression.
The Addenbrooke‘s Cognitive Examination – Revised
(ACE-R) is a brief cognitive dementia screening test bat-
tery recently adapted to Lithuanian population, which
could be recommended as the most appropriate tool for
dementia screening and possibly differential diagnosis
from depression. It has been reported that the ACE-R
could discriminate the cognitive dysfunctions due to de-
pression from that due to dementia [16], although this isnot uniform in all cultural backgrounds [17]. We argue
that ACE-R can be used to differentiate depression from
AD. For the ACE-R to be in differential diagnostics of
depression and AD, culture specific cutoff scores have to
be adjusted [18-20]. The Lithuanian language is different
from English in the length of its words. Lithuanian
words have more syllabeles than their English equiva-
lents. This could explain the lower cut-off poins for the
ACE-R in the Lithuanian-speaking population. In the
validation study of version of the ACE-R in the
Lithuanian-speaking population we identified a lower
cuf-off score of 74 for the detection of dementia [21].
When the lower cut-off score of 74 was used, the sensi-
tivity of the ACE-R to detect dementia was 91%. We
argue that the Lithuanian version of ACE-R with a lower
cut-off score of 74 for dementia could be used for differ-
ential diagnosis of AD and depression. Our study sought
to investigate the ability of the ACE-R to accurately dif-
ferentiate mild-moderate AD from severe depression.Methods
Participants
We recruited the following participants: 85 participants
with early mild-moderate AD, 117 participants with late-
life onset depression (with severe episode), and 94
healthy controls. Consecutive referrals to the Neurology
Department of the Vilnius University Hospital Santariskiu
Clinics were screened for possible inclusion into the study.
Outpatients with late-life onset depression (with severe
episode) fulfilling the criteria for participation in our study
were recruited from the Vilnius City Mental Health
Centre. The inclusion criteria for all the groups are dis-
played in Table 1. Participants were excluded from the
study, if they had a concurrent degenerative CNS disease
(for example, Parkinson’s disease) or other primary
nervous system diseases (for example, epilepsy), an acute
stroke, primary psychiatric disorder (for example, schizo-
phrenia), clinically significant kidney or liver disease,
thyroid dysfunction or vitamin B12 deficiency. All partici-
pants were between 50 and 88 years old at the time of
recruitment and were well matched for age, sex, and edu-
cation. All participants had at least 4 years of education.
Spouses or friends of the participating participants were
recruited as healthy controls. All participants had suffi-
cient knowledge of Lithuanian language to participate in
the study. The majority of control participants were able
to perform all of the tasks in the test. Participants who
had visual problems were asked to wear glasses. None of
the participants had severe hearing or other sensory
impairments. The study and informed consent form was
approved by the Lithuanian Bioethics Committee. Written
informed consent for participation in the study was
obtained from all participants.
Rotomskis et al. BMC Neurology  (2015) 15:57 Page 3 of 8Instrument
Addenbrooke’s Cognitive Examination-Revised (ACE-R)
The ACE-R is a brief, 15–20-min test battery originally de-
signed to detect and classify different kinds of dementia,
particularly AD and frontotemporal dementia, without the
use of specialized test equipment [22]. The ACE-R takes
between 12 and 20 min (average 16) to administer and
score in a clinical setting. It contains 5 subtests, each one
representing one cognitive domain: attention/orientation
(18points), memory (26 points), fluency (14 points), lan-
guage (26 points) and visuospatial (16 points). ACE-R max-
imum score is 100, composed by the addition of the all
subtests.
Statistical analysis
The statistical analysis was carried out with the SPSS for
Windows package. The possible influence of demo-
graphic factors (age, gender and education) on the ACE-
R scores was investigated. A general linear regression
model was formed in order to test whether gender, age
and education have an effect on the ACE-R test scores.
To analyze the extent of utility of the ACE-R scores in
prediction of the presence or absence of clinical diag-
nosis the binominal logistic regression analysis was
used. We applied a receiver operating characteristic
curve (ROC) analysis to examine the sensitivity and
specificity of our measures. One-way ANOVAs and
Mann–Whitney U-tests were carried out to compare
the relevant group means of performance on the ACE-
R test. The Chi square test was used to compare rele-
vant group frequencies.
Results
Demographics
Demographic characteristics of the patient and control
groups are summarized in Table 2. The groups were
matched on age (one-way ANOVA, F[2, 293] = 0.154; p =
0.857), years of education (one-way ANOVA, F[2, 293] =
1.376; p = 0.254) and gender (χ2, p = 0.663).Table 1 Inclusion criteria for the participant recruitment
The patient has probable AD diagnosed according to National Institute of Ne
and Communicative Disorders and Sroke and Alzheimer’s Disease and Relate
Association (NINCDS-ADRDA) criteria at the time of testing [34].
The patient has had a CT or an MRI at the time of diagnosis establishment w
consistent with the diagnosis of probable AD (according to the mandatory s
from the Lithuanian Health Ministry).
The patient has a Mini Mental State Examination (MMSE) score at screening o
and not greater than 23 [35].
Patients fulfilled International Classification of Mental and Behavioural Disord
modification (ICD-10-AM) criteria [21] for severe depression episode at the tim
(code: F32.20). All diagnoses of depression were established by experienced
The patient has a Mini Mental State Examination (MMSE) score at screening oTo evaluate whether the demographic variables had an
effect on performance on the ACE-R test scores, we formed
general linear regression models for the patient and control
groups. In AD group neither age (F = 1.288; Beta = −0.178;
p = 0.110), nor gender (F = 7.588; Beta = −0.034; p = 0.759)
nor education (F = 3.366; Beta = 0.149; p = 0.182) had an ef-
fect on ACE-R scores. In depression group both age had an
effect (F = 12.111; Beta = −0.321; p < 0.001), while educa-
tion (F = 0.339; Beta = −0.113, p = 0.211) and gender did
not (F = 0.200; Beta = −0.061; p = 0.499). In control group
both age (F = 2.174; Beta = −0.387; p < 0.001) and educa-
tion (F = 2.869; Beta = 0.454; p < 0.001) had an effect, while
gender did not (F = 0.101; Beta = 0.025; p = 0.769).
ACE-R clinical utility
We carried out a logistic-regression analysis with two
target variables: patients with AD group versus no-AD
group (depression and healthy controls). The total ACE-
R score correctly classified 93.9% of the cases.
We carried out a ROC analysis with two target vari-
ables: patients with AD group versus no-AD group (de-
pression and healthy controls). The trade-off between
sensitivity (true positive rate) and 1–specificity (false
positive rate) of the ACE-R in diagnosing AD in a pa-
tient population with and without a later confirmed AD
dementia is shown in the ROC curve in Figure 1. The
area under the ROC curve is 0.977, which suggests that
the ACE-R has a high specificity for a large range of sen-
sitivities. At 74, the previously recommended cut-off
score [21] for clinical use in the detection of dementia,
the ACE-R showed a sensitivity of 81%, and a specificity
of 100% for AD in our study.
ACE-R performance in participants with depression, AD
and control groups
The mean scores on the ACE-R of the patient and con-
trol groups are shown in Table 3. A one-way ANOVA
showed a significant between-group difference on ACE-
R. To explore this further, we carried out post-hocAD group Depression group Control group
urological
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f at least 18, +
ers Australian
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psychiatrist.
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f at least 27 [35]. +
Table 2 Demographic characteristics of the patient and control groups
Total Mild-moderate AD Late-life onset depression
(with severe episode)
Controls
Females in percent 64.5% 63.5% 67.5% 67.0%
Mean age in years (SD) 66.52 (±8.76) 66.33 (±7.92) 66.33 (±8.08) 66.93 (±10.26)
Years of education (SD) 11.48 (±3.33) 11.15 (±3.41) 11.36 (±3.59) 11.93 (±2.86)
Note. SD: Standard deviation.
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impairment relative to the control group (Bonferroni
p < 0.001). The AD group showed significant impairment
relative to depression group (Bonferroni; p < 0.001). The
depression group showed significant impairment relative
to control group (Bonferroni; p < 0.001). Participants with
AD tend to fail the ACE-R (score below the recommended
cut-off of 74 points) significantly more often than par-
ticipants with severe depression or controls (chi square;
p < 0.001). In addition, more participants with depres-
sion fail ACE-R than controls (chi square; p < 0.001). In
the AD group 100% of participants fell below the cut-off
score, in the depression group – 23.9%, in the control
group – 8.5%.
Because the depression group was likely to score
statistically significantly lower than the control group,
we ran a series of ANOVAs to test for differences be-
tween group performances in each of the ACE-RFigure 1 Receiver Operating Characteristics (ROC) of the Addenbrooke’s C
line is the ROC curve, the black line is the diagonal line.subtests. To explore this further, we carried out post-hoc
pairwise comparisons. The AD groups showed signifi-
cant impairment relative to the control group (Bonfer-
roni p < 0.001). The impairment was severe, because the
AD group scored in the range of more than three stand-
ard deviations below performance of controls. Also, the
AD group showed significant impairment relative to de-
pression group (Bonferroni; p < 0.001). The depression
group showed no significant impairment relative to
control group (Bonferroni; p = 0.067). The AD groups
showed significant impairment relative to the control
group (Bonferroni p < 0.001). The impairment was severe,
because the AD group scored in the range of more than
three standard deviations below performance of controls.
Also, the AD group showed significant impairment rela-
tive to depression group (Bonferroni; p < 0.001). The de-
pression group showed significant impairment relative to
control group (Bonferroni; p < 0.001). The impairmentognitive Examination-Revised (ACE-R) as a Test for AD. Note. The blue
Table 3 Addenbrooke’s Cognitive Examination - Revised (ACE-R) and its subtests means, and standard deviations in
patient and control groups (in parenthesis SD)*
Mild-moderate AD Late-life onset depression Controls F[df1,df2] p value
ACE-R total 54.74 (12.19) 76.82 (7.36) 85.08 (7.20) 271,7 [2, 293] <0.001
Attention and orientation 11.80 (2.93) 17.00 (1.65) 17.65 (0.71) 307.98 [2, 293] <0.001
Memory 8.25 (3.47) 13.79 (6.29) 18.52 (3.38) 93.05 [2, 293] <0.001
Verbal fluency 6.07 (2.74) 8.33 (2.12) 10.56 (2.16) 83.19 [2, 293] <0.001
Language 17.21 (4.04) 23.21 (2.73) 23.56 (2.17) 125.99 [2, 293] <0.001
Visuospatial abilities 11.40 (2.70) 14.41 (1.64) 14.78 (1.69) 76.09 [2, 293] <0.001
*Results of post-hoc analysis in detail are displayed in the text.
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in the range of one to two standard deviations below the
controls. The AD groups showed significant impairment
relative to the control group (Bonferroni p < 0.001). The
impairment was moderate, because the AD group scored
in the range of two to three standard deviations below per-
formance of controls. Also, the AD group showed signifi-
cant impairment relative to depression group (Bonferroni;
p < 0.001). The depression group showed significant impair-
ment relative to control group (Bonferroni; p < 0.001). The
impairment was considered mild, because the depression
group scored in the range of one to two standard deviations
below the controls. The AD groups showed significant
impairment relative to the control group (Bonferroni
p < 0.001). The impairment was mild, because the AD
group scored in the range of two to three standard devia-
tions below performance of controls. Also, the AD group
showed significant impairment relative to depression
group (Bonferroni; p < 0.001). The depression group
showed significant impairment relative to control group
(Bonferroni; p < 0.001). The impairment was considered
mild, because the depression group scored in the range of
one to two standard deviations below the controls. To ex-
plore this further, we carried out post-hoc pairwise com-
parisons. The AD groups showed significant impairment
relative to the control group (Bonferroni p < 0.001). The
impairment was severe, because the AD group scored in
the range of more than three standard deviations below
performance of controls. Also, the AD group showed
significant impairment relative to depression group
(Bonferroni; p < 0.001). The depression group showed
no significant impairment relative to control group
(Bonferroni; p = 1). To explore this further, we carried
out post-hoc pairwise comparisons. The AD groups
showed significant impairment relative to the control
group (Bonferroni p < 0.001). The impairment was mild,
because the AD group scored in the range of one to
two standard deviations below performance of controls.
Also, the AD group showed significant impairment
relative to depression group (Bonferroni; p < 0.001).
The depression group showed no significant impair-
ment relative to control group (Bonferroni; p = 1).Because we found mild impairments of orientation
and attention, memory and verbal fluency subtests in
the depression group, we compared the differences be-
tween the groups on memory and verbal fluency tasks.
We used Mann–Whitney U-test to compare ACE-R per-
formance of AD and depression groups. A series of
Mann–Whitney U-tests revealed significant mean differ-
ences (Table 4) between the groups for all memory tasks.
We ran a series of ANOVAs to test for differences be-
tween group performances in each of the verbal fluency
subtest tasks. A one-way ANOVA showed a significant
between-group difference on the letter fluency task
(Table 5). The AD groups showed significant impairment
relative to the control group (Bonferroni p < 0.001). Also,
the depression group showed significant impairment
relative to the control group (Bonferroni; p < 0.001). The
AD group showed no significant impairment relative to
the depression group (Bonferroni; p = 1). A one-way
ANOVA showed a significant between-group difference
on the category fluency task (Table 5). The AD groups
showed significant impairment relative to the control
group (Bonferroni p < 0.001). Also, the AD group
showed significant impairment relative to the depression
group (Bonferroni; p < 0.001). The depression group
showed no significant impairment relative to the control
group (Bonferroni; p < 0.001).
Because analysis of the neuropsychological profiles’ of
depression and AD showed that these diseases have distinct
neuropsychological impairments on the ACE-R, we inven-
stigated, how diagnostic accuracy may be improved by ana-
lyzing the neuropsychological profiles. A logistic-regression
analysis using the domain scores of orientation, attention,
category fluency, memory and language of the ACE-R again
to predict membership in the target groups with and with-
out a progressive-degenerative dementia indicated a satis-
factorily high proportion, 97.8%, of the observed cases
correctly predicted. A higher proportion of observed cases
were correctly by using the identified domain scores.
Discussion
The earlier studies established the Lithuanian version of
Addenbrooke’s Cognitive Examination-Revised to be a
Table 4 Means and standard deviations of memory subtest tasks in the AD and depression groups (in parenthesis SD)
Mild-moderate AD Late-life onset depression p Value Z-score
Recall 0.8 (0.69) 1.65 (1.03) <0.001 −5.894
Anterograde memory 3.53 (1.34) 4.40 (2.23) <0.001 −3.612
Retrograde memory 1.87 (0.99) 2.56 (0.94) <0.001 −4.684
Address recall 0.55 (0.89) 2.27 (2.28) <0.001 −6.033
Address recognition 1.52 (1.18) 3.01 (1.64) <0.001 −6.443
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to organic pathology [21]. We have extended this work
by investigating, how ACE-R can be used in differential
diagnostics in depression and AD.
The demographic differences had no effect on the
study results, because the AD, depression and control
groups did not differ significantly by age, gender or edu-
cation. In our study age had a significant influence on
ACE-R performance in depression and control groups
(in line with previous findings by Margeviciute et al.,
[21]), which again emphasizes the need for age-specific
ACE-R norms. Having the importance of age on overall
performance in mind, it appears to be worthwhile to
consider establishing different ACE-R cutoff points for
the young-old and the old-old groups in Lithuanian-
speaking population later on in the result analysis, as
had been done in the Pigliautille and colleagues’ [23]
adaptation of ACE-R. Future research in this field is
needed to test this hypothesis.
In this study we have shown ACE-R to be a useful
tool, which with high accuracy was able to detect par-
ticipants with cognitive deficits due to AD and differen-
tiate them from participants with late-life onset severe
depression or healthy controls. The ACE-R displayed
high clinical utility (high sensitivity and specificity). Despite
this, participants with depression were likely to have a
lower score in ACE-R than the control group. This per-
tained that participants with depression were statistically
significantly more likely than the healthy controls to be
identified as having dementia with ACE-R. This way we
have replicated in our sample the problem of dementia-
depression differentiation that is common in clinical prac-
tice. This led to a further analysis of the ACE-R subtests
scores, how depression influenced the performance on
ACE-R.
Further analysis of the neuropsychological profiles’ of
depression and AD showed that these diseases have dis-
tinct neuropsychological impairments on the ACE-R.
AD was characterized by severely impaired performanceTable 5 Means and standard deviations of verbal fluency task
Mild-moderate AD Late-life onset de
Letter fluency 3.49 (1.52) 3.65 (1.21)
Category fluency 2.58 (1.45) 4.68 (1.23)
*Results of post-hoc analysis in detail are displayed in the text.on attention and orientation, memory and language sub-
tests, and moderately impaired performance on verbal
fluency subtest. Meanwhile, mild impairment in the total
ACE-R score, along with a low score on the memory
and verbal fluency subtest tasks, characterized partici-
pants with depression. Memory and verbal fluency im-
pairments found in depression are distinct from those
found in AD. Memory deficits in AD group are different
from those found in depression group. AD was charac-
terized by more severe impairment of category fluency,
while the depression was characterized by more severe
selective impairment of letter fluency.
Considering the neuropsychological profile of the AD
group on the ACE-R, it is consistent with the research
on cognitive decline in early AD. Memory decline is the
commonest complaint of participants and, more often,
of their caregivers in AD. This is most commonly seen
in the domain of anterograde episodic memory, that is
the encoding storage, retention, and recall of new infor-
mation about day-to-day personal experiences, which
are accompanied by mild impairments in retrograde
memory with a temporal gradient such that more distant
memories are the most intact [24,25]. Consistent with
previous research, we found accompanying deficits in
attentional mechanisms, language and category flu-
ency [25-27]. Considering visuospatial abilities in AD,
visuoperceptual and visuospatial deficits are seldom
clinically evident in the early stages of AD, with the
notable exception of those participants who present
with visual agnosia, the visual variant of AD [28]. This
explains the occasionally found mild visuospatial defi-
cits in AD group.
Considering the neuropsychological profile of depres-
sion, the results are mostly consistent with previous re-
search. As expected memory impairment in AD seems
to be more severe than in depression [29]. Memory tasks
in the ACE-R could discriminate AD from depression.
Although participants with late-life onset severe depres-
sion tended to score significantly lower than controls,s in the subject groups (in parenthesis SD)*
pression Controls F[df1, df2] p value
5.21 (1.25) 49,06 [2, 293] <0.001
4.7 (1.3) 107,12 [2, 293] <0.001
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than participants with AD. Moving to the verbal fluency
findings, the depression group was characterized by let-
ter fluency deficits and unimpaired semantic fluency,
while in AD group category fluency deficits were signifi-
cantly more severe than letter fluency deficits. Semantic
memory impairments are detected in mild-moderate
AD. On tests of verbal fluency, category fluency per-
formance of patients with AD is more impaired than
letter fluency, indicating difficulty accessing the seman-
tic lexicon of word meanings [27]. In comparison to the
extensive literature of letter- and category-based fluency
in AD, relatively little attention has been paid to verbal
fluency in affective disorders. Some researchers have
found no significant difference between depressed and
normal-comparison subjects [30], whereas others have
reported impairment [31,32]. Studies consistent with
our research have reported impaired letter but unim-
paired semantic fluency in depressed elderly subjects
[33], but more research is needed.
Although participants scoring below the cut-off score
for dementia on ACE-R are likely to have AD not de-
pression, we argue that these disorders should be differ-
entiated by analyzing the neuropsychological profile of
impairments. Mild impairment in the ACE-R total score
with mild memory and greater deficits in letter fluency
than in category fluency is indicative of depression not
AD. Meanwhile, severe attention and orientation, mem-
ory and language deficits, greater deficits in semantic
fluency than in letter fluency, and occasionally found
mild impairments in visuospatial abilities are features
attributable to AD.
Conclusions
ACE-R has diagnostic accuracy in detecting people
with AD and can be used in differential diagnostics
of depression and AD. When interpreting the results
it is important to compare the overall pattern of per-
formance across all five subtests to verify the diagnosis,
because depression and AD have distinct neuropsy-
chological profiles. AD was characterized by severely
impaired performance on attention and orientation,
memory and language subtests, and moderately im-
paired performance on verbal fluency subtest. Mean-
while, mild impairment in the total ACE-R score, along
with a low score on the memory and verbal fluency sub-
test tasks, characterized participants with depression.
Memory and verbal fluency impairments found in de-
pression are distinct from those found in AD. Memory
deficits in depression are less severe than in AD, letter
fluency is more impaired than category fluency, while in
AD category fluency is more impaired than letter flu-
ency. To sum up, ACE-R can be used in differential
diagnostics of AD and depression.Competing interests
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